Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
·RxPONDER, an independent study led by SWOG Cancer Research Network,
demonstrates that guiding treatment with Oncotype DX test can spare
chemotherapy use in majority of postmenopausal women
·Results have already led to updated NCCN Guidelines® for breast cancer
·New RxPONDER results to be featured in oral presentation at 2021 San Antonio
Breast Cancer Symposium (SABCS)
MADISON, Wis., December 1, 2021 – Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine.[i] The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25. Initial results from RxPONDER were reported at the 2020 San Antonio Breast Cancer Symposium (SABCS). The findings have now been confirmed in this peer-reviewed publication.
